Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: A PharmacoVigilance study in France

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 885-888

  Danton, Anne Charlotte ^a   Montastruc, François ^a,b,c   Sommet, Agnès ^a,b,c   Durrieu, Geneviève ^a,b,c   Bagheri, Haleh ^a,b,c   Bondon Guitton, Emmanuelle ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Montastruc, Jean Louis ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

Adverse drug reactions; Drug interactions; P450 cytochromes; Pharmacovigilance

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMLODIPINE; BUDESONIDE; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DICLOFENAC; DIHYDROERGOTAMINE; DILTIAZEM; ESOMEPRAZOLE; FLUCONAZOLE; GALANTAMINE; GLIMEPIRIDE; HALOPERIDOL; IRBESARTAN; LANSOPRAZOLE; METHYLPREDNISOLONE; MIRTAZAPINE; PANTOPRAZOLE; PREDNISOLONE; RISPERIDONE; TACROLIMUS; TELITHROMYCIN; TRAMADOL; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZOPICLONE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; AGITATION; ARTICLE; CLINICAL ARTICLE; CONFUSION; DATA BASE; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; EXTRAPYRAMIDAL SYNDROME; FEMALE; FRANCE; HALLUCINATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; LUNG FIBROSIS; MALAISE; MALE; MELENA; MOUTH INFECTION; MYALGIA; MYCOSIS; NAUSEA; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; TREMOR; VISUAL HALLUCINATION; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; FRANCE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PHARMACOVIGILANCE;

EID: 84876723364     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1394-3     Document Type: Article

References (19)

1. Gonzalez F, Tukey R (2006) Drug Metabolism. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill Companies, NewYork, pp 71-91
2. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-21
3. Prescrire Rédaction (2011) Eviter les effets indésirables par Interactions Médicamenteuses: comprendre et décider. Rev Prescrire 31:416
4. Lewis LD (2010) Drug-drug interactions: Is there an optimal way to study them? Br J Clin Pharmacol 70:781-3
5. Jankel CA, Fiterman LK (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9:51-9
6. Egger T, Dormann H, Ahne G, Runge U, Neubert A, Criegee-Rieck M, Gassmann KG, Brune K (2003) Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 20:769-76
7. Leone R, Magro L, Moreti U, Cuttroneo P, Moschini M, Motola D, Tuccori M, Conforti A (2012) Identifying adverse drug reactions associated with drug-drug interactions. Drug Saf 33:667-75
8. Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL (2012) The importance of drug-drug interactions as a cause of adverse drug reactions: A pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 68:767-75
9. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL (1995) French pharmaco vigilance database system: Examples of utilization. Therapie 50:557-62
10. Edwards IR, Aronson JK (2000) Adverse drug reactions: Definitions, diagnosis and management. Lancet 356:1255-9
11. Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities. Drug Saf 2:109-117
12. center d'Informations Thérapeutiques et de PharmacoVigilance, Service de Pharmacologie et Toxicologie Cliniques, Hôpitaux Universitaires de Genève (Switzerland). Interactions Médicamenteuses et Cytochromes P 450. http://pharmacoclin.hug-ge.ch/-library/pdf/cytp450.pdf
13. Dictionnaire VIDAL. 86th ed. Paris: O.V.P. eds. 2010
14. Remy N, Lapeyre-Mestre M, Bareille MP, Montastruc JL (2000) Drug interactions: A prospective pilot study in primary health care. Therapie 55:395-398
15. Egger T, Dormann H, Ahne G, Pahl A, Runge U, Azaz-Livshits T, Neubert A, Criegee-Rieck M, Gassmann KG, Brune K (2005) Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions: A pilot study. Drugs Aging 22:265-75
16. Fletcher CV (2010) Drug Interactions should be evaluated in patients. Clin Pharmacol Ther 88:5857
17. Philips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of Pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286:2270-2279
18. Becquemont L (2009) Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10:961-969
19. Magro L, Moreti U, Leone R (2012) Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf 11:83-94